FIRST AMENDMENT TO AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • August 6th, 2013 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
This First Amendment to the Amended and Restated License and Collaboration Agreement (this "First Amendment") dated as of May 1, 2013 (the "First Amendment Effective Date"), is by and between Regeneron Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of New York and having its principal office at 777 Old Saw Mill River Road, Tarrytown, New York 10591 ("Regeneron") and Aventis Pharmaceuticals Inc., a corporation organized and existing under the laws of the State of Delaware and having a principal place of business at 55 Corporate Drive, Bridgewater, New Jersey 08807 ("Sanofi"), an indirect wholly-owned subsidiary of sanofi-aventis, a company organized under the laws of France with its principal headquarters at 174, avenue de France, 75013 Paris, France, with each of Sanofi and Regeneron being sometimes referred to herein individually or as a “Party” and collectively as the “Parties”.)
SANOFI LETTERHEAD]Discovery and Preclinical Development Agreement • August 6th, 2013 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations
Reference is hereby made to the Amended and Restated Discovery and Preclinical Development Agreement (the “Discovery Agreement”), dated as of November 10, 2009, by and between Aventis Pharmaceuticals Inc., a Delaware corporation with a principal place of business located at 55 Corporate Drive, Bridgewater, New Jersey 08807, an indirect wholly owned subsidiary of Sanofi-Aventis, a company organized under the laws of France with its principal headquarters at 174, avenue de France, 75013, Paris, France, and Regeneron Pharmaceuticals, Inc., a New York corporation with a principal place of business located at 777 Old Saw Mill River Road, Tarrytown, New York 10591. Capitalized terms used herein and not otherwise defined herein shall have the defined meanings set forth in the Discovery Agreement.
AMENDED AND RESTATED NON-EXCLUSIVE LICENSE AND SETTLEMENT AGREEMENTNon-Exclusive License and Settlement Agreement • August 6th, 2013 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Amended and Restated Non-Exclusive License and Settlement Agreement (“Agreement”) is entered into as of the Amendment Effective Date, and is effective as of the Effective Date, by and between Genentech, Inc. (“Genentech”), a Delaware corporation having its principal place of business at 1 DNA Way, South San Francisco, California 94080 and Regeneron Pharmaceuticals, Inc. (“Licensee”), a New York corporation having its principal place of business at 777 Old Saw Mill River Road, Tarrytown, NY 10591.
ELEVENTH AMENDMENT TO LEASELease • August 6th, 2013 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations
THIS ELEVENTH AMENDMENT TO LEASE (this “Eleventh Amendment”) is entered into as of this 3rd day of April, 2013 (the “Execution Date”), by and between BMR-LANDMARK AT EASTVIEW LLC, a Delaware limited liability company (“Landlord”), and REGENERON PHARMACEUTICALS, INC., a New York corporation (“Tenant”).
NON-EXCLUSIVE LICENSE AND SETTLEMENT AGREEMENTNon-Exclusive License and Settlement Agreement • August 6th, 2013 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Non-Exclusive License and Settlement Agreement (“Agreement”) is entered into as of the Effective Date by and between Genentech, Inc. (“Genentech”), a corporation organized and existing under the laws of Delaware; Regeneron Pharmaceuticals, Inc., (“Regeneron”), a corporation organized and existing under the laws of New York; Sanofi U.S. Services, Inc. (formerly known as Sanofi-Aventis U.S. Inc.), a corporation organized and existing under the laws of Delaware; and Sanofi-Aventis U.S. LLC, a limited liability company organized and existing under the laws of Delaware (the latter two entities collectively referred to as “Sanofi”).
TWELFTH AMENDMENT TO LEASELease • August 6th, 2013 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations
IN WITNESS WHEREOF, Tenant has executed this Acknowledgment of Term Commencement Date and Term Expiration Date as of the date first written above.
THIS AGREEMENT is dated the 17th day of May, 2013 and made BETWEEN AND AMONG:Collaboration Agreement • August 6th, 2013 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • England and Wales
THIRTEENTH AMENDMENT TO LEASELease • August 6th, 2013 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations
IN WITNESS WHEREOF, Tenant has executed this Acknowledgment of 777 [North Spine][Northwest Lobby] Level Premises Commencement Date as of the date first written above.
MT. PLEASANT LEASE by and betweenLease Agreement • August 6th, 2013 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
NOTHING IN THESE RULES AND REGULATIONS (“RULES AND REGULATIONS”) SHALL SUPPLANT ANY PROVISION OF THE LEASE. IN THE EVENT OF A CONFLICT OR INCONSISTENCY BETWEEN THESE RULES AND REGULATIONS AND THE LEASE, THE LEASE SHALL PREVAIL.
